| | | | | | | | | | | | | | | | | | | | | | |
| <?xml version="1.0" encoding="windows-1252"?> |
| <ownershipDocument> |
| <schemaVersion> X0306 </schemaVersion> |
| <documentType> 4 </documentType> |
| <periodOfReport> 2021-10-29 </periodOfReport> |
| <notSubjectToSection16> 1 </notSubjectToSection16> |
| <issuer> |
| | <issuerCik> 0000880432 </issuerCik> |
| | <issuerName> MISONIX INC </issuerName> |
| | <issuerTradingSymbol> MSON </issuerTradingSymbol> |
| | </issuer> |
| <reportingOwner> |
| | <reportingOwnerId> |
| | | <rptOwnerCik> 0001789574 </rptOwnerCik> |
| | | <rptOwnerName> Koby Michael </rptOwnerName> |
| | | </reportingOwnerId> |
| | <reportingOwnerAddress> |
| | | <rptOwnerStreet1> C/O MISONIX, INC. </rptOwnerStreet1> |
| | | <rptOwnerStreet2> 1938 NEW HIGHWAY </rptOwnerStreet2> |
| | | <rptOwnerCity> FARMINGDALE </rptOwnerCity> |
| | | <rptOwnerState> NY </rptOwnerState> |
| | | <rptOwnerZipCode> 11735 </rptOwnerZipCode> |
| | | <rptOwnerStateDescription></rptOwnerStateDescription> |
| | | </reportingOwnerAddress> |
| | <reportingOwnerRelationship> |
| | | <isDirector> 1 </isDirector> |
| | | <isOfficer> 0 </isOfficer> |
| | | <isTenPercentOwner> 0 </isTenPercentOwner> |
| | | <isOther> 0 </isOther> |
| | | <officerTitle></officerTitle> |
| | | <otherText></otherText> |
| | | </reportingOwnerRelationship> |
| | </reportingOwner> |
| <nonDerivativeTable> |
| | <nonDerivativeTransaction> |
| | | <securityTitle> |
| <value> Common Stock </value> |
| </securityTitle> |
| | | <transactionDate> |
| <value> 2021-10-29 </value> |
| </transactionDate> |
| | | <deemedExecutionDate></deemedExecutionDate> |
| | | <transactionCoding> |
| <transactionFormType> 4 </transactionFormType> |
| <transactionCode> D </transactionCode> |
| <equitySwapInvolved> 0 </equitySwapInvolved> |
| </transactionCoding> |
| | | <transactionTimeliness></transactionTimeliness> |
| | | <transactionAmounts> |
| <transactionShares> |
| <value> 1744017 </value> |
| <footnoteId id="F1"/> |
| <footnoteId id="F2"/> |
| <footnoteId id="F3"/> |
| </transactionShares> |
| <transactionPricePerShare> |
| <footnoteId id="F1"/> |
| <footnoteId id="F2"/> |
| <footnoteId id="F3"/> |
| </transactionPricePerShare> |
| <transactionAcquiredDisposedCode> |
| <value> D </value> |
| </transactionAcquiredDisposedCode> |
| </transactionAmounts> |
| | | <postTransactionAmounts> |
| <sharesOwnedFollowingTransaction> |
| <value> 0 </value> |
| </sharesOwnedFollowingTransaction> |
| </postTransactionAmounts> |
| | | <ownershipNature> |
| <directOrIndirectOwnership> |
| <value> I </value> |
| </directOrIndirectOwnership> |
| <natureOfOwnership> |
| <value> By 1315 Capital Management, LLC </value> |
| <footnoteId id="F4"/> |
| </natureOfOwnership> |
| </ownershipNature> |
| | | </nonDerivativeTransaction> |
| | </nonDerivativeTable> |
| <footnotes> |
| | <footnote id="F1"> Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers"). </footnote> |
| | <footnote id="F2"> Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. </footnote> |
| | <footnote id="F3"> Includes 50,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement). </footnote> |
| | <footnote id="F4"> The reporting person is a member of 1315 Capital Management, LLC. Under the Amended and Restated Limited Liability Company Agreement of 1315 Capital Management, LLC, the reporting person is deemed to hold the reported option for the benefit of 1315 Capital, LLC ("1315"), and must exercise the option solely upon the direction of 1315, which is entitled to the shares issued upon exercise. 1315 may be deemed the indirect beneficial owner of the option, and the reporting person may be deemed the indirect beneficial owner of the option through his indirect interest in 1315. The reporting person disclaims beneficial ownership of the option except to the extent of his pecuniary interest therein. </footnote> |
| | </footnotes> |
| <ownerSignature> |
| | <signatureName> /s/ Michael Koby </signatureName> |
| | <signatureDate> 2021-12-08 </signatureDate> |
| | </ownerSignature> |
| </ownershipDocument> |
